Genelux Co. (NASDAQ:GNLX - Get Free Report) major shareholder Aladar Szalay sold 6,403 shares of Genelux stock in a transaction on Monday, April 29th. The stock was sold at an average price of $3.25, for a total transaction of $20,809.75. Following the transaction, the insider now owns 1,249,327 shares in the company, valued at approximately $4,060,312.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Aladar Szalay also recently made the following trade(s):
- On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total value of $109,101.30.
- On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total value of $28,224.00.
- On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $50,588.43.
- On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.
Genelux Stock Up 5.5 %
Shares of GNLX opened at $3.28 on Thursday. The company has a 50 day simple moving average of $5.41 and a two-hundred day simple moving average of $10.31. Genelux Co. has a 1 year low of $3.06 and a 1 year high of $40.98.
Look Who Fired the World’s Richest Man
From Banyan Hill Publishing | Ad
This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S.
And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.
Get the full story here.
Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). On average, analysts forecast that Genelux Co. will post -0.81 EPS for the current year.
Hedge Funds Weigh In On Genelux
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Woodward Diversified Capital LLC increased its stake in Genelux by 0.3% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company's stock worth $6,983,000 after acquiring an additional 3,687 shares during the last quarter. Vanguard Group Inc. increased its position in Genelux by 1,660.1% in the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company's stock worth $24,025,000 after purchasing an additional 925,258 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Genelux by 476.6% during the third quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company's stock valued at $1,321,000 after purchasing an additional 44,584 shares in the last quarter. AMG National Trust Bank bought a new position in Genelux during the third quarter valued at $1,233,000. Finally, LifeSteps Financial Inc. grew its stake in shares of Genelux by 26.6% in the 1st quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company's stock worth $285,000 after buying an additional 9,301 shares in the last quarter. 37.33% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on GNLX. Benchmark reissued a "speculative buy" rating and issued a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright decreased their price target on Genelux from $35.00 to $32.00 and set a "buy" rating on the stock in a report on Tuesday, April 2nd.
View Our Latest Stock Report on Genelux
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
